Apr 15, 2013 by Dave WilliamsonElan Investors Receive Royal TreatmentElan's sweet new royalties deal.
Apr 15, 2013 by Dave WilliamsonHow "60 Minutes" Killed HMAThe award winning show had a big negative impact on the hospital's first quarter.
Apr 14, 2013 by Dave Williamson and Max MacalusoHealth Care's Biggest Movers and ShakersAcadia soared, HMA tumbled, and a trio of stocks became the FDA's new Breakthrough Crew.
Apr 14, 2013 by Dave Williamson and Max MacalusoThe Flu: Peril, Profit, and PreventionThe avian flu grips china while drugmakers profit from the treatment of and prevention.
Apr 14, 2013 by Dave Williamson and Max MacalusoObama and Business Agree: Punish the UnhealthyIs penalizing unhealthy habits the secret to lowering health-care costs?
Apr 14, 2013 by Dave Williamson1 Monster Medical Malpractice VerdictUnitedHealth gets hit with $500 million in punitive damages.
Apr 12, 2013 by Dave WilliamsonWall Street Backs the Wrong BiotechAre these Wall Street upgrades really deserved?
Apr 12, 2013 by Dave WilliamsonThe Answer to Obamacare's Exploding CostsCould this be the answer to Obamacare's implementation costs?
Apr 12, 2013 by Dave Williamson, Brenton Flynn, and Max MacalusoAn Obesity Drugmaker's Critical Coming WeeksWhy Arena Pharmaceuticals should be on your radar.
Apr 11, 2013 by Dave WilliamsonAcadia Leaps Toward the Finish LineShares of Acadia Pharmaceuticals exploded today. What's behind this stock price skyrocket?
Apr 10, 2013 by Dave WilliamsonAnd the Bidding War Winner Is ...Who's going to win the bidding war over Life Technologies, and will it pay off big for investors?
Apr 9, 2013 by Dave WilliamsonThe Hidden Danger of Eating Red MeatA new study sheds more light on red meat and why consumers may want to re-evaluate one supplement.
Apr 9, 2013 by Dave WilliamsonThis Bidding War Was a Bidding SkirmishThe bidding war for Obagi Medical Products is over, and everyone's a winner.
Apr 8, 2013 by Dave Williamson and Max MacalusoHealth Care's Best Stock: Celgene vs. Abbott LabsThe Motley Fool's exclusive health-care stock tournament crowns a champion.
Apr 7, 2013 by Dave Williamson, Brenton Flynn, and Max MacalusoThe New Cure for Seasonal AllergiesWhile there remains no cure for Bieber Fever, seasonal allergy sufferers have an exciting new hope from Merck.
Apr 7, 2013 by Dave Williamson, Brenton Flynn, and Max MacalusoWhy Investors Need to Watch Alkermes This extended release technology company could bring extended returns to shareholders.
Apr 7, 2013 by Dave Williamson, Brenton Flynn, and Max MacalusoThe Next Potential Global Pandemic Is it time to get worried again over China's avian flu? And what stocks hold the cure for investors portfolios?
Apr 7, 2013 by Dave Williamson, Brenton Flynn, and Max MacalusoIs Obamacare Turning Pharmacies Into Doctors? And where consumers can shop for the cheapest generic drugs.
Apr 6, 2013 by Dave Williamson and Max MacalusoFinal Four Stocks: Celgene vs. Johnson & JohnsonThe Motley Fool's exclusive health-care stock tournament moves closer to crowning a champion.
